Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Orozco, Javier I. J|||0000-0003-2585-358X
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Valdez, Betsy
  • Wang, Chuan
  • Mezger, Anja|||0000-0002-7337-9547
  • Choi, Eunkyoung
  • Tran, Yan Zhou
  • Yao, Liqun
  • Bonath, Franziska
  • Olsen, Remi-André
  • Ormestad, Mattias
  • Esteller, M|||0000-0003-4490-6093
  • Lupien, Mathieu|||0000-0003-0929-9478
  • Marzese, Diego|||0000-0002-3258-8852
Objectives: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Unlike other breast cancer subtypes, the scarcity of specific therapies and greater frequencies of distant metastases contribute to its aggressiveness. We aimed to find epigenetic changes that aid in the understanding of the dissemination process of these cancers. Data description: Using CRISPR/Cas9, our experimental approach led us to identify and disrupt an insulator element, IE8, whose activity seemed relevant for cell invasion. The experiments were performed in two well-established TNBC cellular models, the MDA-MB-231 and the MDA-MB-436. To gain insights into the underlying molecular mechanisms of TNBC invasion ability, we generated and characterized high-resolution chromatin interaction (Hi-C) and chromatin accessibility (ATAC-seq) maps in both cell models and complemented these datasets with gene expression profiling (RNA-seq) in MDA-MB-231, the cell line that showed more significant changes in chromatin accessibility. Altogether, our data provide a comprehensive resource for understanding the spatial organization of the genome in TNBC cells, which may contribute to accelerating the discovery of TNBC-specific alterations triggering advances for this devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer

  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Orozco, Javier I. J.|||0000-0003-2585-358X
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Baker, Jennifer L.
  • Salomon, Matthew P.
  • Martí, Mercè|||0000-0002-1846-0043
  • DiNome, Maggie L.|||0000-0002-1926-292X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Marzese, Diego|||0000-0002-3258-8852
Immune checkpoint inhibitors (ICI) improve clinical outcomes in triple-negative breast cancer (TNBC) patients. However, a subset of patients does not respond to treatment. Biomarkers that show ICI predictive potential in other solid tumors, such as levels of PD-L1 and the tumor mutational burden, among others, show a modest predictive performance in patients with TNBC. We built machine learning models based on pre-ICI treatment gene expression profiles to construct gene expression classifiers to identify primary TNBC ICI-responder patients. This study involved 188 ICI-naïve and 721 specimens treated with ICI plus chemotherapy, including TNBC tumors, HR+/HER2- breast tumors, and other solid non-breast tumors. The 37-gene TNBC ICI predictive (TNBC-ICI) classifier performs well in predicting pathological complete response (pCR) to ICI plus chemotherapy on an independent TNBC validation cohort (AUC = 0.86). The TNBC-ICI classifier shows better performance than other molecular signatures, including PD-1 (PDCD1) and PD-L1 (CD274) gene expression (AUC = 0.67). Integrating TNBC-ICI with molecular signatures does not improve the efficiency of the classifier (AUC = 0.75). TNBC-ICI displays a modest accuracy in predicting ICI response in two different cohorts of patients with HR + /HER2- breast cancer (AUC = 0.72 to pembrolizumab and AUC = 0.75 to durvalumab). Evaluation of six cohorts of patients with non-breast solid tumors treated with ICI plus chemotherapy shows overall poor performance (median AUC = 0.67). TNBC-ICI predicts pCR to ICI plus chemotherapy in patients with primary TNBC. The study provides a guide to implementing the TNBC-ICI classifier in clinical studies. Further validations will consolidate a novel predictive panel to improve the treatment decision-making for patients with TNBC. Triple-Negative Breast Cancer (TNBC) is an aggressive type of breast cancer, responsible for a substantial burden of breast cancer-related deaths. In recent years, immunotherapy, a therapy that triggers the patient's immune system to attack the tumor, has arisen as a promising treatment in various cancers, including TNBC. However, a subset of patients with TNBC does not respond to this treatment. Here, we employed advanced computational techniques to predict response to immunotherapy plus chemotherapy in patients with primary TNBC. Our method is more accurate than using other existing markers, such as PD-L1, but is not very accurate in patients with non-TNBC breast cancers or non-breast cancers. This method could potentially be used to better select patients for immunotherapy, upfront, avoiding the side effects and costs of treating patients in which immunotherapy might not work. Ensenyat-Mendez et al. construct a gene expression-based machine learning classifier to predict the response of triple-negative breast cancer to immune checkpoint inhibition combined with chemotherapy. Predictive performance of the 37-gene classifier is better than that of PD-1 or PD-L1.